GlassScriptPhysician profile
Pablo R Castro
NPI 1538422316
$5,980.90
in general payments reported to CMS, 2019-2025
26 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 92% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,794 · 2020: $385 · 2022: $455 · 2023: $1,229 · 2024: $1,030 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,340 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.23 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,510.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $698.42 | 2019-2024 | Lokelma, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $672.20 | 2019-2020 | |
| Lilly USA, LLC | $623.13 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $315.52 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $264.14 | 2023-2025 | |
| Glaxosmithkline, LLC. | $234.45 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $210.80 | 2023-2025 | Vraylar |
| Silk Road Medical, INC. | $206.16 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.54 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $123.54 | 2019-2023 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $122.88 | 2019 | |
| Abbott Laboratories | $120.30 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $105.24 | 2019-2024 | Otezla, Repatha |
| Smith+Nephew, INC. | $100.59 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $97.47 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $78.64 | 2025 | |
| Boston Scientific Corporation | $59.24 | 2019 | |
| Astellas Pharma US INC | $46.95 | 2024 | Veozah |
| Scilex Pharmaceuticals INC. | $42.43 | 2019 | |
| Sumitomo Pharma America, INC. | $41.60 | 2024-2025 | Gemtesa |
| Dynavax Technologies Corporation | $32.71 | 2023 | Heplisav-B |
| Lundbeck LLC | $28.31 | 2025 | Rexulti |
| Globus Medical, INC. | $18.65 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $14.59 | 2020 | |
| Sanofi Pasteur INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.